BACKGROUND AND OBJECTIVES
Plasma phosphorylated tau (p-tau) 217 is increasingly used for Alzheimer disease (AD) diagnosis and treatment decisions but may be discordant with established AD biomarkers. False-positive (FP) plasma results may lead to overtreatment and false-negative (FN) results to missed or delayed diseas...
D. Shir, A. Algeciras-Schimnich, Y. Piura et al.· Neurology· 0 citations
TAR DNA-binding protein of 43 kDa (TDP-43) is often found in the brains of patients with Alzheimer’s disease (AD), where it co-occurs with amyloid β plaques and tau neurofibrillary tangles, and associates with accelerated cognitive decline and brain atrophy. TDP-43’s function of repressing the inclusion of cryptic exon...
Madison M. Reeves, Sara Aviles Carpintero, M. Zanovello et al.· Alzheimer's Research & Thera...· 0 citations
These findings uncover protein signatures that reflect underlying AD biology and provide a foundation for stage-specific biomarkers and therapeutic targeting, with important implications for patient stratification and personalized intervention strategies.
Saima Rathore, E. Dammer, Anantharaman Shantaraman et al.· Molecular Neurodegeneration· 0 citations
Plasma p‐tau217 and p‐tau217/Aβ42 reliably identify non‐Hispanic White individuals with symptomatic and pre‐clinical AD. However, performance across ethnoracially diverse groups remains unknown.
Y. Piura, P. Aduen, Leah Schecter et al.· Alzheimer's & Dementia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
